Nicolas Dulphy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nicolas Dulphy has a total of 658 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Toubert
Université Paris Cité, Institut de Recherche Saint Louis, INSERM UMR1342, Paris, France
60 shared publications Meriem Messaoudene
19 shared publications- Alexandra Frazao
INSERM U1160, Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris, France
18 shared publications Dominique Charron
18 shared publicationsAnne Caignard
17 shared publications- Christine Sedlik
Institut Curie, PSL Research University, INSERM U932, Paris, France
17 shared publications
Latest Publications
- 9 November 2026
- Published by Springer Nature in Leukemia
- p. 1-12
Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells
Myelodysplastic neoplasms (MDS) are clonal hematopoietic stem cell disorders that frequently progress to secondary acute myeloid leukemia (sAML). Besides intrinsic genetic changes, the disease’s development is heavily influenced by the bone marrow (BM) microenvironment, especially mesenchymal stromal cells (MSCs). In this study, we present a comprehensive characterization of how unhealthy MSCs affect natural killer (NK) cell anti-leukemic function in MDS and sAML. Using integrated ATAC-seq and RNA-seq profiling, we show that MDS/sAML-derived MSCs induce profound chromatin remodeling in NK cells, marked by reduced promoter accessibility and downregulation of genes essential for stress response and survival. Functionally, pathological MSCs fail to deliver the protective support normally provided by healthy MSCs, instead driving mitochondrial fragmentation and apoptosis in NK cells, ultimately suppressing their cytotoxic activity. Together, these findings reveal a previously unrecognized loss of supportive capacity in pathological MSCs that hampers NK-cell fitness. Therapeutic approaches that bolster mitochondrial resilience in NK cells may help counteract this microenvironment-induced impairment and strengthen immune surveillance in MDS and sAML.
- 9 November 2026
- Published by Springer Nature in Leukemia
- p. 1-12
Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells
Myelodysplastic neoplasms (MDS) are clonal hematopoietic stem cell disorders that frequently progress to secondary acute myeloid leukemia (sAML). Besides intrinsic genetic changes, the disease’s development is heavily influenced by the bone marrow (BM) microenvironment, especially mesenchymal stromal cells (MSCs). In this study, we present a comprehensive characterization of how unhealthy MSCs affect natural killer (NK) cell anti-leukemic function in MDS and sAML. Using integrated ATAC-seq and RNA-seq profiling, we show that MDS/sAML-derived MSCs induce profound chromatin remodeling in NK cells, marked by reduced promoter accessibility and downregulation of genes essential for stress response and survival. Functionally, pathological MSCs fail to deliver the protective support normally provided by healthy MSCs, instead driving mitochondrial fragmentation and apoptosis in NK cells, ultimately suppressing their cytotoxic activity. Together, these findings reveal a previously unrecognized loss of supportive capacity in pathological MSCs that hampers NK-cell fitness. Therapeutic approaches that bolster mitochondrial resilience in NK cells may help counteract this microenvironment-induced impairment and strengthen immune surveillance in MDS and sAML.
- 12 October 2026
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 518
CBP inhibition and histone H3K18 hypoacetylation induced by the hematotoxic benzene metabolite 1,4-benzoquinone
- 12 October 2026
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 518
CBP inhibition and histone H3K18 hypoacetylation induced by the hematotoxic benzene metabolite 1,4-benzoquinone
- Open Access
- 6 October 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (11)
A Novel MR Elastography Device for Preclinical Applications From Spheroids to Rodents: Design, Validation, and Performance Evaluation
Magnetic resonance elastography (MRE) is a powerful technique for assessing tissue biomechanics noninvasively. To disentangle and understand the histopathological and cellular signature of changes in tissue biomechanics, preclinical studies remain indispensable. Yet, the preclinical research setting for MRE is currently characterized by a multitude of different hardware solutions designed by different research groups that are often tailored to a single preclinical application. This impedes comparability and reproducibility between the results obtained within the community. This study presents the design, fabrication, and validation of a novel multipurpose preclinical MRE device allowing the examination of rodents, ex vivo tissue samples, and spheroids/organoids. Validation, stability, and reproducibility experiments were conducted on ultrasound gel phantoms. Highly reproducible maps of tissue mechanics are also demonstrated in rodent models and ex vivo biological samples, showing a high degree of concordance with underlying anatomical structures. Beyond established preclinical MRE applications, this methodology opens new avenues for multicenter biomechanical studies in small animal models and ex vivo specimens, with potential applications in oncology, regenerative medicine, and drug testing.
- 6 October 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (11)
Open AccessA Novel MR Elastography Device for Preclinical Applications From Spheroids to Rodents: Design, Validation, and Performance Evaluation
Magnetic resonance elastography (MRE) is a powerful technique for assessing tissue biomechanics noninvasively. To disentangle and understand the histopathological and cellular signature of changes in tissue biomechanics, preclinical studies remain indispensable. Yet, the preclinical research setting for MRE is currently characterized by a multitude of different hardware solutions designed by different research groups that are often tailored to a single preclinical application. This impedes comparability and reproducibility between the results obtained within the community. This study presents the design, fabrication, and validation of a novel multipurpose preclinical MRE device allowing the examination of rodents, ex vivo tissue samples, and spheroids/organoids. Validation, stability, and reproducibility experiments were conducted on ultrasound gel phantoms. Highly reproducible maps of tissue mechanics are also demonstrated in rodent models and ex vivo biological samples, showing a high degree of concordance with underlying anatomical structures. Beyond established preclinical MRE applications, this methodology opens new avenues for multicenter biomechanical studies in small animal models and ex vivo specimens, with potential applications in oncology, regenerative medicine, and drug testing.
- 16 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (16) , 1950-1963
Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an autoinflammatory disorder caused by acquired somatic ubiquitin like modifier activating enzyme 1 (UBA1) mutations in hematopoietic stem cells, affecting peripheral myeloid and natural killer (NK) cells. Given the high rate of severe infections in patients with VEXAS, we hypothesized that NK-cell dysfunction contributes to this susceptibility. We conducted a comprehensive immune characterization of peripheral NK cells in patients with VEXAS (n = 40), patients with autoinflammatory diseases without UBA1 mutations (n = 22), and older sex-matched healthy controls (n = 16). Multiparameter phenotyping used cytometry by time-of-flight, single-cell RNA sequencing (scRNA-seq), whole-blood stimulation assays, and in vitro NK-cell cytotoxic assay. Peripheral NK cells in VEXAS were quantitatively and qualitatively impaired. Mass cytometry revealed reduced frequencies of mature cytotoxic CD56dim NK cells and expansion of the CD56high CD16dim subset. NK cells exhibited exhaustion features, including increased programmed cell death protein 1 expression, and reduced cytotoxic markers such as NKp46 and CD8α. scRNA-seq analysis showed decreased signatures of cytotoxicity and interleukin-2 (IL-2) and interferon gamma (IFN-γ) production, alongside increased inflammatory signatures. Whole-blood stimulation assays confirmed impaired IL-2, IFN-γ, and granzyme B production following Toll-like receptor 3 (TLR3), TLR4, and TLR7/TLR8 agonist stimulation. Extended NK phenotyping by flow cytometry confirmed reduced activating receptors’ expression and impaired IFN-γ production in VEXAS syndrome. Moreover, in vitro UBA1 inhibitors impaired NK-cell cytotoxic capacity and promote cell death. Finally, reduced NK-cell frequencies were independently associated with an increased risk of severe infections. These findings suggest that NK-cell dysfunction in VEXAS syndrome contributes to increased susceptibility to severe infections.
- 16 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (16) , 1950-1963
Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an autoinflammatory disorder caused by acquired somatic ubiquitin like modifier activating enzyme 1 (UBA1) mutations in hematopoietic stem cells, affecting peripheral myeloid and natural killer (NK) cells. Given the high rate of severe infections in patients with VEXAS, we hypothesized that NK-cell dysfunction contributes to this susceptibility. We conducted a comprehensive immune characterization of peripheral NK cells in patients with VEXAS (n = 40), patients with autoinflammatory diseases without UBA1 mutations (n = 22), and older sex-matched healthy controls (n = 16). Multiparameter phenotyping used cytometry by time-of-flight, single-cell RNA sequencing (scRNA-seq), whole-blood stimulation assays, and in vitro NK-cell cytotoxic assay. Peripheral NK cells in VEXAS were quantitatively and qualitatively impaired. Mass cytometry revealed reduced frequencies of mature cytotoxic CD56dim NK cells and expansion of the CD56high CD16dim subset. NK cells exhibited exhaustion features, including increased programmed cell death protein 1 expression, and reduced cytotoxic markers such as NKp46 and CD8α. scRNA-seq analysis showed decreased signatures of cytotoxicity and interleukin-2 (IL-2) and interferon gamma (IFN-γ) production, alongside increased inflammatory signatures. Whole-blood stimulation assays confirmed impaired IL-2, IFN-γ, and granzyme B production following Toll-like receptor 3 (TLR3), TLR4, and TLR7/TLR8 agonist stimulation. Extended NK phenotyping by flow cytometry confirmed reduced activating receptors’ expression and impaired IFN-γ production in VEXAS syndrome. Moreover, in vitro UBA1 inhibitors impaired NK-cell cytotoxic capacity and promote cell death. Finally, reduced NK-cell frequencies were independently associated with an increased risk of severe infections. These findings suggest that NK-cell dysfunction in VEXAS syndrome contributes to increased susceptibility to severe infections.
- Open Access
- 2 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Modeling mesenchymal stromal cell support to hematopoiesis within a novel 3D artificial marrow organoid system
The human bone marrow (BM) microenvironment involves hematopoietic and non-hematopoietic cell subsets organized in a complex architecture. Tremendous efforts have been made to model it in order to analyze normal or pathological hematopoiesis and its stromal counterpart. Herein, we report an original, fully-human in vitro 3D model of the BM microenvironment dedicated to study interactions taking place between mesenchymal stromal cells (MSC) and hematopoietic stem and progenitor cells (HSPC) during the hematopoietic differentiation. This fully-human Artificial Marrow Organoid (AMO) model is highly efficient to recapitulate MSC support to myeloid differentiation and NK cell development from the immature CD34 + HSPCs to the most terminally differentiated CD15 + polymorphonuclear neutrophils, CD64 + monocytes or NKG2A-KIR2D + CD57 + NK subset. Lastly, our model is suitable for evaluating anti-leukemic NK cell function in presence of therapeutic agents. Overall, the AMO is a versatile, low cost and simple model able to recapitulate normal hematopoiesis and allowing more physiological drug testing by taking into account both immune and non-immune BM microenvironment interactions.
- 2 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessModeling mesenchymal stromal cell support to hematopoiesis within a novel 3D artificial marrow organoid system
The human bone marrow (BM) microenvironment involves hematopoietic and non-hematopoietic cell subsets organized in a complex architecture. Tremendous efforts have been made to model it in order to analyze normal or pathological hematopoiesis and its stromal counterpart. Herein, we report an original, fully-human in vitro 3D model of the BM microenvironment dedicated to study interactions taking place between mesenchymal stromal cells (MSC) and hematopoietic stem and progenitor cells (HSPC) during the hematopoietic differentiation. This fully-human Artificial Marrow Organoid (AMO) model is highly efficient to recapitulate MSC support to myeloid differentiation and NK cell development from the immature CD34 + HSPCs to the most terminally differentiated CD15 + polymorphonuclear neutrophils, CD64 + monocytes or NKG2A-KIR2D + CD57 + NK subset. Lastly, our model is suitable for evaluating anti-leukemic NK cell function in presence of therapeutic agents. Overall, the AMO is a versatile, low cost and simple model able to recapitulate normal hematopoiesis and allowing more physiological drug testing by taking into account both immune and non-immune BM microenvironment interactions.
- Open Access
- 30 October 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (23)
Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosis
Despite the advances in the understanding and treatment of myeloproliferative neoplasm (MPN), the disease remains incurable with the risk of evolution to acute myeloid leukemia or myelofibrosis (MF). Unfortunately, the evolution of the disease to MF remains poorly understood, impeding preventive and therapeutic options. Recent studies in solid tumor microenvironment and organ fibrosis have shed instrumental insights on their respective pathogenesis and drug resistance, yet such precise data are lacking in MPN. In this study, through a patient sample–driven transcriptomic and epigenetic description of the MF microenvironment landscape and cell-based analyses, we identify homeobox B7 (HOXB7) overexpression and more precisely a potentially novel TGF-β/WNT/HOXB7 pathway as associated to a pro-fibrotic and pro-osteoblastic biased differentiation of mesenchymal stromal cells (MSCs). Using gene-based and chemical inhibition of this pathway, we reversed the abnormal phenotype of MSCs from patients with MF, providing the MPN field a potentially novel target to prevent and manage evolution to MF.
- 30 October 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (23)
Open AccessComprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosis
Despite the advances in the understanding and treatment of myeloproliferative neoplasm (MPN), the disease remains incurable with the risk of evolution to acute myeloid leukemia or myelofibrosis (MF). Unfortunately, the evolution of the disease to MF remains poorly understood, impeding preventive and therapeutic options. Recent studies in solid tumor microenvironment and organ fibrosis have shed instrumental insights on their respective pathogenesis and drug resistance, yet such precise data are lacking in MPN. In this study, through a patient sample–driven transcriptomic and epigenetic description of the MF microenvironment landscape and cell-based analyses, we identify homeobox B7 (HOXB7) overexpression and more precisely a potentially novel TGF-β/WNT/HOXB7 pathway as associated to a pro-fibrotic and pro-osteoblastic biased differentiation of mesenchymal stromal cells (MSCs). Using gene-based and chemical inhibition of this pathway, we reversed the abnormal phenotype of MSCs from patients with MF, providing the MPN field a potentially novel target to prevent and manage evolution to MF.
- 29 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (860) , eadl5100
CXCR4 signaling determines the fate of hematopoietic multipotent progenitors by stimulating mTOR activity and mitochondrial metabolism
Both cell-intrinsic and niche-derived, cell-extrinsic cues drive the specification of hematopoietic multipotent progenitors (MPPs) in the bone marrow, which comprise multipotent MPP1 cells and lineage-restricted MPP2, MPP3, and MPP4 subsets. Patients with WHIM syndrome, a rare congenital immunodeficiency caused by mutations that prevent desensitization of the chemokine receptor CXCR4, have an excess of myeloid cells in the bone marrow. Here, we investigated the effects of increased CXCR4 signaling on the localization and fate of MPPs. Knock-in mice bearing a WHIM syndrome–associated CXCR4 mutation ( CXCR4 1013 ) phenocopied the myeloid skewing of bone marrow in patients. Whereas MPP4 cells in wild-type mice differentiated into lymphoid cells, MPP4s in CXCR4 1013 knock-in mice differentiated into myeloid cells. This myeloid rewiring of MPP4s in CXCR4 1013 knock-in mice was associated with enhanced signaling mediated by the kinase mTOR and increased oxidative phosphorylation (OXPHOS). MPP4s also localized further from arterioles in the bone marrow of knock-in mice compared with wild-type mice, suggesting that the loss of extrinsic cues from the perivascular niche may also contribute to their myeloid skewing. Chronic treatment with the CXCR4 antagonist AMD3100 or the mTOR inhibitor rapamycin restored the lymphoid potential of MPP4s in knock-in mice. Thus, CXCR4 desensitization drives the lymphoid potential of MPP4 cells by dampening the mTOR-dependent metabolic changes that promote myeloid differentiation.
- 29 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (860) , eadl5100
CXCR4 signaling determines the fate of hematopoietic multipotent progenitors by stimulating mTOR activity and mitochondrial metabolism
Both cell-intrinsic and niche-derived, cell-extrinsic cues drive the specification of hematopoietic multipotent progenitors (MPPs) in the bone marrow, which comprise multipotent MPP1 cells and lineage-restricted MPP2, MPP3, and MPP4 subsets. Patients with WHIM syndrome, a rare congenital immunodeficiency caused by mutations that prevent desensitization of the chemokine receptor CXCR4, have an excess of myeloid cells in the bone marrow. Here, we investigated the effects of increased CXCR4 signaling on the localization and fate of MPPs. Knock-in mice bearing a WHIM syndrome–associated CXCR4 mutation ( CXCR4 1013 ) phenocopied the myeloid skewing of bone marrow in patients. Whereas MPP4 cells in wild-type mice differentiated into lymphoid cells, MPP4s in CXCR4 1013 knock-in mice differentiated into myeloid cells. This myeloid rewiring of MPP4s in CXCR4 1013 knock-in mice was associated with enhanced signaling mediated by the kinase mTOR and increased oxidative phosphorylation (OXPHOS). MPP4s also localized further from arterioles in the bone marrow of knock-in mice compared with wild-type mice, suggesting that the loss of extrinsic cues from the perivascular niche may also contribute to their myeloid skewing. Chronic treatment with the CXCR4 antagonist AMD3100 or the mTOR inhibitor rapamycin restored the lymphoid potential of MPP4s in knock-in mice. Thus, CXCR4 desensitization drives the lymphoid potential of MPP4 cells by dampening the mTOR-dependent metabolic changes that promote myeloid differentiation.
- Open Access
- 10 August 2024
- Published by Springer Nature in Research Square
CD56neg CD16+ cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML.
CD56neg CD16+ Natural Killer (NK) cells have been reported to expand in chronic diseases and acute myeloid leukemia (AML). However, their biological role is still unclear. Using mass cytometry, spectral flow cytometry, bulk RNA-seq and in vitro assays, we characterized CD56neg CD16+ NK cells that expand in AML. We confirmed that CD56neg CD16+ NK cells represent a unique NK cell subset coexpressing Eomes and T-bet. CD56neg CD16+ NK cells could recover CD56 expression in vitro where they displayed unaltered NK cell functions. We previously demonstrated that CD56neg CD16+ NK cells expansion at diagnosis was associated with adverse clinical outcome in AML. Here, we validated our findings in a validation cohort of N=38 AML patients. AML patients with CD56neg CD16+ NK cells expansion at diagnosis had decreased overall survival (HR[CI95]=5.5[1.2-24.5], p=0.0251) and relapse-free survival (HR[CI95]=13.1[1.9-87.5], p=0.0079) compared to AML patients without expansion after 36 months follow-up. RNA-seq unveiled that CD56neg CD16+ NK cells were mature circulating NK cells with functional capacities. Upon expansion, CD56neg CD16+ NK cells from AML patients showed altered proteomic phenotype, with high expression of TIM-3 and Siglec-7. Taken together, our results suggest that CD56neg CD16+ NK cells are a relevant target for future NK-cell-based immunotherapies.
- 10 August 2024
- Published by Springer Nature in Research Square
Open AccessCD56neg CD16+ cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML.
CD56neg CD16+ Natural Killer (NK) cells have been reported to expand in chronic diseases and acute myeloid leukemia (AML). However, their biological role is still unclear. Using mass cytometry, spectral flow cytometry, bulk RNA-seq and in vitro assays, we characterized CD56neg CD16+ NK cells that expand in AML. We confirmed that CD56neg CD16+ NK cells represent a unique NK cell subset coexpressing Eomes and T-bet. CD56neg CD16+ NK cells could recover CD56 expression in vitro where they displayed unaltered NK cell functions. We previously demonstrated that CD56neg CD16+ NK cells expansion at diagnosis was associated with adverse clinical outcome in AML. Here, we validated our findings in a validation cohort of N=38 AML patients. AML patients with CD56neg CD16+ NK cells expansion at diagnosis had decreased overall survival (HR[CI95]=5.5[1.2-24.5], p=0.0251) and relapse-free survival (HR[CI95]=13.1[1.9-87.5], p=0.0079) compared to AML patients without expansion after 36 months follow-up. RNA-seq unveiled that CD56neg CD16+ NK cells were mature circulating NK cells with functional capacities. Upon expansion, CD56neg CD16+ NK cells from AML patients showed altered proteomic phenotype, with high expression of TIM-3 and Siglec-7. Taken together, our results suggest that CD56neg CD16+ NK cells are a relevant target for future NK-cell-based immunotherapies.
- Open Access
Generation of natural killer and myeloid cells in a 3D artificial marrow organoid system
The human bone marrow (BM) microenvironment involves hematopoietic and non-hematopoietic cell subsets organized in a complex architecture. Tremendous efforts have been made to model it in order to analyse normal or pathological hematopoiesis and its stromal counterpart. Herein, we report an original, fully-human in vitro 3D model of the BM microenvironment dedicated to study interactions taking place between mesenchymal stromal cells (MSC) and hematopoietic stem and progenitor cells (HSPC) during the hematopoietic differentiation. This artificial marrow organoid (AMO) model is highly efficient to support NK cell development from the CD34+ HSPC to the terminally differentiated NKG2A-KIR2D+CD57+ NK subset. In addition, myeloid differentiation can also be recapitulated in this model. Moreover, mature NK cell phenotype showed significant differences in the AMO compared to a conventional 2D coculture model for the expression of adhesion molecules and immune checkpoint receptors, thus better reflecting the NK cell behaviour in the BM microenvironment. Lastly, we proved that our model is suitable for evaluating anti-leukemic NK cell function in presence of treatments. Overall, the AMO is a versatile, low cost and simple model able to efficiently recapitulate hematopoiesis and granting better drug response taking into account both immune and non-immune BM microenvironment interactions. Graphical
Open AccessGeneration of natural killer and myeloid cells in a 3D artificial marrow organoid system
The human bone marrow (BM) microenvironment involves hematopoietic and non-hematopoietic cell subsets organized in a complex architecture. Tremendous efforts have been made to model it in order to analyse normal or pathological hematopoiesis and its stromal counterpart. Herein, we report an original, fully-human in vitro 3D model of the BM microenvironment dedicated to study interactions taking place between mesenchymal stromal cells (MSC) and hematopoietic stem and progenitor cells (HSPC) during the hematopoietic differentiation. This artificial marrow organoid (AMO) model is highly efficient to support NK cell development from the CD34+ HSPC to the terminally differentiated NKG2A-KIR2D+CD57+ NK subset. In addition, myeloid differentiation can also be recapitulated in this model. Moreover, mature NK cell phenotype showed significant differences in the AMO compared to a conventional 2D coculture model for the expression of adhesion molecules and immune checkpoint receptors, thus better reflecting the NK cell behaviour in the BM microenvironment. Lastly, we proved that our model is suitable for evaluating anti-leukemic NK cell function in presence of treatments. Overall, the AMO is a versatile, low cost and simple model able to efficiently recapitulate hematopoiesis and granting better drug response taking into account both immune and non-immune BM microenvironment interactions. Graphical
- Open Access
- 21 December 2023
- Published by Springer Nature in Blood Cancer Journal
- Vol. 13 (1) , 1-5
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
- 21 December 2023
- Published by Springer Nature in Blood Cancer Journal
- Vol. 13 (1) , 1-5
Open AccessLymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M